Патент USA US2105197код для вставки
Patented Jan. 11,, 1.938 2,105,197 UNI-TED STATES PATENT o'rrilca 2,105,197 MEDICAMENT Adelia McCrea, Detroit, Mich, assignor to Parke, ' Davis & Company, Detroit, Mich, a corpora tion of Michigan ' No Drawing. , Application July 13, 1931, Serial No. 550,630 7 Cs. (6]. 167-63) The invention relates to a therapeutic agent small amounts of essential oils or other materials useful in treating certain fungous infections such for imparting a pleasant odor to the mixture.‘ as dermatomycosis, epidermomycosis and epi An example of a prefered formula is as follows: dermophytosis. This disease is very common 5 throughout the entire world and is often referred ‘ Per cent 5 Lanolin _______________________________ __ _80 to as “athlete's foot-itch”, “dhobie itch”, “jockey .‘strap itch”, etc. It is caused by certain fungi Water ___________________________ _. ____ __ l0 among which Trichophyton interdigitale is one Petrolatum ____________________________ .. 9 of the most resistant forms. 10 - White wax _____________________________ __ My invention resides in the discovery of a new 6 Chlorbutanol (trichlortertiary butyl alco ‘ class of medicaments for the treatment of the hol) _________ __'______________________ __ 5 above mentioned disease and more particularly to certain compositions for eliminating the fun gous infection without causing pain or irritability 15 of the infected tissues. Salicylic acid __________________________ __ Mercury salicylate _____________________ __ 4 4': The therapeutic agent made in accordance with my invention contains in its preferred form at least two main ingredients; ?rst a material for keratolyzing and desquamating the tissues of 20 fungous lesions, and second a material for re lieving the irritation caused by the kerotolyzing and desquamating action. The ?rst material may be selected from a wide' variety of substances such for example as: Sali 25 cylic acid, mercury salicylate, phenols, tar oint ment, benzoic acid. The above materials may be used either singly or in suitable combinations. ‘ ‘It is also to be understood that other substances 30 may be-substituted for those’ listed providing they have the required kerotolyzing and desqua mating properties. - The second material of the formula may be selected from three or more diiierent classes, all of which are of an anesthetic nature and are capable of reducing the irritability caused by 'keratolyzing and desquamating.v One of the ' classes comprises materials which are merely anesthetic in their action such as butyn, novo A second class comprises materials which are not only anesthetic but also fungistatic agents such as chlorbutanol and brombutanol. The third class comprises materials that are fun gicidal as well as mild anesthetic agents and includes such materials as the high molecular 40 caine, etc. Sodium citrate _________________________ __ 1 Oil of cloves ___________________________ __ Oil of cinnamon _______ _'_ _______________ __ 0.5 0.5 100 Another formula coming within the purview of the invention is: 20 ‘ Per cent Lanolin ____'______\ _____________________ __ 60 Water _________________________________ _- 10 Petrolatum ____________________________ __ 9 White wax ______________ __‘_ ____________ __ 25 Chlorbutanol (trichlortertiary butyl alco hol) _________________________________ __ 5 Salicylic acid __________________________ _. Benzoic acid _____ __' ____________________ ...'. 3 5 Sodium citrate ________________ _; _______ __ 1 Oil of cloves ___________________________ __ 0.5 - Oil of cinnamon ____ _; __________________ __ 0.5 30 100 Another modi?cation of the invention contains: Per cent ,Phenol _________________________________ __ 2 Zinc oxide ________ _-; ___________________ __ 20 Tar ointment ___________________________ __ 23 Ointment of rose water__________________ __ 50 Chlorbutanol ____ __ _______ __, _______ -s ____ __- 5 100 In the speci?c examples given above the com weight phenols and polyhalogenated phenols. ponent for reducing irritability of the mixture ‘ Examples are trichlorphenol, tribromphenol and is chlorbutanol. However, it is to be understood bromnaphthol, etc. ' In preparing a therapeutic agent in accordance . that, other materials as heretofore listed may be . with my invention suitable proportions of the' substituted for the chlorbutanol. In certain broader aspects, my invention con two main ingredients above discussed are com sists in the discovery that chlorbutanol and other bined preferably in a suitable carrier adapted to halogenated tertiary butyl alcohols have a fun form a salve. The carrier may be selected from gistatic action on Trichophyton interdz'gitale and such materials as lanolin, wax, petrolatum, cocoa other fungi which cause dermatomycosis, epi 55 butter, etc., and usually has incorporated therein 10 dermomycosis and epidermophytosis and are . 9,108,197 2 . bene?cial in inhibiting proliferation of the fun gus causing "athlete's foot-itc ". Thus it comes within the purview of. the in vention to incorporate chlorbutanol and its equiv alent homologues in any therapeutic agent for the topical treatment of fungus infections of the type of dermatomycosis, epidermomycosis and epidermophytosis where the newly discovered “ properties may be used for combating Trichophy 10 ton interdz‘gitctle and other fungi causing der matomycosis, epidermomycosls and epldermophy tosis. What I claim as my invention is: 1. A therapeutic agent for treatment of fun 15 gous infection of the type of dermatomycosis, epi dermomycosis and epidermophytosis comprising an ointment base, salicylic acid, mercury salioyl~ ate and chlorbutanol. 2. A therapeutic agent for treatment of derma 20 tomycosis, epidermomycosis and epidermophyto siscomprising a keratolyzing and desquamating agent of the class consisting of salicylic acid, mer cury salicylate, phenols, tar ointment and ben zoic acid and a material incorporated therein of 25 the class consisting of butyn, novocaine, chlor butanol, brombutanol, trichlorphenol, tribrom phenol and bromnaphthol. ' 3. A therapeutic agent for the ‘topical treat“ ment of fungus infections of the type of derma 30 tomycosis, epidermomycosis and epidermophytosis comprising a salicylic acid compound having a keratolyzing and desquamating action and a halogenated tertiary butyl alcohol capable of re lieving the irritation caused by said salicylic acid 35 compound at the site of said fungus infections and having a fungistatic action on said fungus infections. 4. A therapeutic agent for the topical treat ment of fungus infections including Triciwphyton interdioitale and other fungi causing dermato mycosis, epidermomycosis and epidermcphytosis comprising a salicylic acid compound having a lzeratolyzing and desquamating action and chlor butanol capable of relieving the irritation caused by said salicylic acid compound at the site of said infections and having a fungistatic action on said infections. 5. A therapeutic agent for the topical treat ‘ment of fungus infections of the type of derma 10 tomycosis, epidermomycosis and epidermophyto sis comprising an ointment including lanolin, petrolatum. and wax, a keratolyzing and des quamating agent including salicyclic acid and mercury salicylate and chlorbutanol in amount 15 su?cient to relieve the irritation caused by said keratolyzing and desquamating agent at the site of said fungus infections and having a fungistatic action on said fungus infections. 6. A'therapeutic agent for the topical treat 20 ment of fungus infections of the type of derma tomycosis, epidermomycosis . and epidermophyto sis having substantially the following composi tion:-lanolin 60%, water 10%, petrolatum 9%, white wax, 6%, chlorbutanol 5%, salicylic acid 25 4%, mercury salicylate 4% and sodium citrate 1%. 7. A therapeutic agent for the topical treat ment of fungus infections including Trichophyton interdigitale and other fungi causing dermatomy cosis, epidermomycosls and epidermophytosis comprising an ointment base, a salicylic acid compound having a keratolyzing and desquamat~ ing action and chlorbutanol in an amount on the order of 5% having fungicidal action on Tri chophyton interdigitale and having anesthetic action adapted to counteract irritation caused by - said salicylic acid compound. I ADELIA McCREA.